How is PIK used at the holdco level via shareholder loans, and what does it do to returns and the cap table?
A core Private Equity interview question — asked in analyst and associate interviews across IB, PE, and the Big 4.
THE SHORT ANSWER
Sponsors often fund part of their investment as a holdco shareholder loan (or preferred) that pays interest 'in kind' (PIK) — accruing and compounding rather than paying cash — sitting above the management ordinary equity in the waterfall. The PIK instrument compounds a fixed return for the sponsor before any value reaches the ordinary (sweet) equity, which gears management's payoff (they only share value above the accrued preferred) and lets the sponsor capture a base return even on a flat outcome. It also has tax features in some jurisdictions (interest deductibility, subject to limitation rules). Effects: it doesn't drain operating cash (PIK accrues), it boosts the sponsor's downside-protected return and shapes the management incentive, and at exit the accrued PIK is paid off the top of the equity proceeds. The constraint is structuring rules — interest-deduction limitations and the risk it overwhelms management's incentive if set too high.
WHAT INTERVIEWERS LISTEN FOR
- ✓Holdco shareholder loan/pref with PIK accrues, ranks above ordinary equity
- ✓Compounds a sponsor return before sweet equity shares value
- ✓No cash drain on the business; downside-protects sponsor return
- ✓Watch interest-deduction limits and over-gearing management out
COMMON MISTAKES
- ✗Confusing holdco PIK with operating-company debt
- ✗Ignoring the waterfall ranking above ordinary equity
- ✗Not noting tax/deduction limitation rules
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you handle a covenant breach?
- How would you assess a carve-out opportunity for PE?
- When would you use PIK (Payment-in-Kind) debt?
- What's the difference between an equity cure and a capital injection?
- How do PE firms handle underperforming portfolio companies?
- How does a PE fund handle currency risk in cross-border deals?